Therapeutic flag Noindex: medium evidence

Gamolenic Acid

CAS 506-26-3

Gamolenic Acid (CAS 506-26-3) is a Phase 3 pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
10
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Gamolenic Acid
CAS Number
506-26-3
UNII
78YC2MAX4O
InChIKey
VZCCETWTMQHEPK-QNEBEIHSSA-N
ChEMBL ID
CHEMBL464982
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL464982 | Small molecule
SOURCE EMBL-EBI ChEMBL 10 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 27363.475 nM 32 -
- Potency 36816.02285714286 nM 28 -
- IC50 14061.25 nM 8 -
- EC50 4620 nM 1 -
3-oxo-5-alpha-steroid 4-dehydrogenase 2
Enzyme
IC50 4.85 - Homo sapiens
Peroxisome proliferator-activated receptor alpha
Nuclear hormone receptor
IC50 6.57 - Homo sapiens
Peroxisome proliferator-activated receptor gamma
Nuclear hormone receptor
IC50 5.66 - Homo sapiens
Peroxisome proliferator-activated receptor delta
Nuclear hormone receptor
IC50 6.12 - Homo sapiens
Free fatty acid receptor 1
GPCR
EC50 5.33 - Homo sapiens
Tissue factor
Membrane receptor
IC50 4.52 - Homo sapiens
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Gamolenic Acid used for in pharmaceutical contexts?

Gamolenic Acid (CAS 506-26-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Gamolenic Acid?

No adverse-event association or SIDER side-effect rows are rendered for Gamolenic Acid in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Gamolenic Acid also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Gamolenic Acid.

What clinical phase is Gamolenic Acid in?

Gamolenic Acid is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Gamolenic Acid?

Gamolenic Acid has 10 bioactivity rows in this page query. Rendered target entries include 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma, Peroxisome proliferator-activated receptor delta, Free fatty acid receptor 1.